Company: BSX
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000885725-25-000011
Chunk: 125

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 8
Chunk 125
---
 equity: Preferred stock, $0.01 par value - authorized 50,000,000 shares; 0 shares issued as of December 31, 2024 and 2023— — Common stock, $0.01 par value - authorized 2,000,000,000 shares; 1,737,846,196 shares issued as of December 31, 2024 and 1,729,000,224 shares issued as of December 31, 202317 17 Treasury stock, at cost - 263,289,848 shares as of December 31, 2024 and 2023(2,251)(2,251)Additional paid-in capital21,056 20,647 Retained earnings2,673 819 Accumulated other comprehensive income (loss), net of tax:275 49 Total stockholders’ equity21,770 19,282 Noncontrolling interests233 248 Total equity22,003 19,530 TOTAL LIABILITIES AND EQUITY$39,395 $35,136 

See notes to the consolidated financial statements. Amounts may not foot due to rounding.

68

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

Year Ended December 31,(in millions, except share data)202420232022Preferred stock shares issuedBeginning— 10,062,500 10,062,500 Conversion of mandatory convertible preferred stock to common stock— (10,062,500)— Ending— — 10,062,500 Common stock shares issuedBeginning1,729,000,224 1,696,633,993 1,688,810,052 Impact of stock-based compensation plans8,845,972 8,383,329 7,823,941 Conversion of mandatory convertible preferred stock to common stock— 23,982,902 — Ending1,737,846,196 1,729,000,224 1,696,633,993 Preferred stockBeginning$— $0 $0 Conversion of mandatory convertible preferred stock to common stock— (0)— Ending— $— 0 Common stockBeginning$17 $17 $17 Impact of stock-based compensation plans0 0 0 Conversion of mandatory convertible preferred stock to common stock— 0